A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
Condition: Alcoholic Hepatitis Interventions: Drug: DUR-928 30 mg; Drug: DUR-928 90 mg; Drug: Placebo+ Standard of Care (SOC) Sponsors: Durect; CTI Clinical Trial and Consulting Services Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials